Vladimir L.
- Country
- Sweden
- Department
- Hematology, oncology and radiation physics
Research Overview
- Evaluation of CC-95251 Monotherapy and in Combination with Antineoplastic Agents in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes
- Evaluation of Hydroxycarbamide Addition to Cytarabine and Daunorubicin Regimen in Newly Diagnosed Adult Acute Myeloid Leukemia
- Phase II Evaluation of Azacitidine and Low-Dose Venetoclax in Acute Myeloid Leukemia with Multi-Omics and Ex Vivo Drug Screening Integration
Data & Insights
Has run more than one trial at 120 of 251 partner sites.
Specializations
Hematologic Oncology
This clinical investigator specializes in the treatment of acute myeloid leukemia (AML), with particular emphasis on developing innovative therapeutic approaches for both newly diagnosed and treatment-resistant cases.
- Novel Combination Therapies
- FLT3-ITD Mutation Analysis
- Targeted Treatment Strategies
Their research encompasses both standard chemotherapy optimization and targeted molecular approaches.
Therapeutic Development
The investigator focuses on evaluating novel drug combinations, including venetoclax-based regimens and the integration of hydroxyurea enhancement strategies in standard treatment protocols.
- Drug Combination Studies
- Chemotherapy Enhancement
- Treatment Optimization
Their work includes assessment of treatment safety profiles and efficacy in various patient populations.
Advanced Diagnostics
The investigator incorporates multi-omics approaches and minimal residual disease (MRD) monitoring in their research methodology, advancing personalized treatment strategies.
- Biomarker Analysis
- Drug Response Screening
- Treatment Response Assessment
Their research integrates advanced diagnostic techniques with therapeutic interventions.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.